Further, in human and mouse CRC cell lines, combined treatment with adiponectin and metformin, a glycemia-lowering drug used in T2DM, reverses the cancer-inducing effect of IL-1β [49], similarly to non-small-cell lung carcinoma (NSCLC) cells, in which adiponectin inhibits migratory and invasive capacities and induces the expression of epithelial markers while downregulating the mesenchymal markers [50]. Here, ADIPOQ is linked to type 2 diabetes mellitus.